AI English summary of an SEC filing — figures as filed
Baxter International BAXBaxter International said its global net sales in 2025 totaled $11.24 billion, an increase of 6% on a reported basis and 3% on an operational sales basis compared to 2024. U.S. sales were $6.12 billion and international sales were $5.12 billion.
Key points
AI summaryBaxter International said its global net sales in 2025 totaled $11.24 billion, an increase of 6% on a reported basis and 3% on an operational sales basis compared to 2024. U.S. sales were $6.12 billion and international sales were $5.12 billion.
The company said net loss attributable to Baxter stockholders in 2025 totaled $(957) million, or $(1.87) per diluted share, and special items adversely impacted net loss by $2.09 billion, or $4.08 per diluted share. Net loss from continuing operations was $(900) million.
Baxter International said it completed the sale of its Kidney Care business to Carlyle on January 31, 2025 for an aggregate purchase price of $3.80 billion in cash. As of 2025, the company repaid $3.81 billion of legacy indebtedness, primarily with net after-tax cash proceeds from the sale, not including $2.00 billion of indebtedness repaid with proceeds from a new notes offering.
Baxter International said operating cash flows from continuing operations in 2025 totaled $951 million, compared to $819 million in 2024. Capital expenditures in the same year were $513 million and dividend payments were $348 million.
Key figures
Fiscal year ended December 31, 2025
- Revenue
- $11.2B
- Operating income
- −$308M
- Net income
- −$957M
- EPS
- −$1.87
- Gross profit
- $3.4B
- Operating cash flow
- $845M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
2025 Annual Net Sales of $11.24 billion
Baxter International said its global net sales in 2025 totaled $11.24 billion, an increase of 6% on a reported basis and 3% on an operational sales basis compared to 2024. U.S. sales were $6.12 billion and international sales were $5.12 billion.
Source · Based on the MD&A text of the filing
2025 Net Loss and Special Items
The company said net loss attributable to Baxter stockholders in 2025 totaled $(957) million, or $(1.87) per diluted share, and special items adversely impacted net loss by $2.09 billion, or $4.08 per diluted share. Net loss from continuing operations was $(900) million.
Source · Based on the MD&A text of the filing
Sale of Kidney Care Business and Debt Repayment
Baxter International said it completed the sale of its Kidney Care business to Carlyle on January 31, 2025 for an aggregate purchase price of $3.80 billion in cash. As of 2025, the company repaid $3.81 billion of legacy indebtedness, primarily with net after-tax cash proceeds from the sale, not including $2.00 billion of indebtedness repaid with proceeds from a new notes offering.
Source · Based on the MD&A text of the filing
2025 Operating Cash Flows and Capital Expenditures
Baxter International said operating cash flows from continuing operations in 2025 totaled $951 million, compared to $819 million in 2024. Capital expenditures in the same year were $513 million and dividend payments were $348 million.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…